Singh Preeti, Fletcher Terry W, Li Yicong, Rusch Nancy J, Kilic Fusun
Department of Biochemistry and Molecular Biology, College of Medicine, The University of Arkansas for Medical Sciences, Little Rock, USA.
Health (Irvine Calif). 2013 Mar 1;5(4A):31-39. doi: 10.4236/health.2013.54A005.
Angiotensin II (Ang II) is a critical component of the renin-angiotensin system that contributes to hypertension. Although platelets in blood from hypertensive subjects have an abnormal biological profile, it is unclear if circulating Ang II influences platelet aggregation or thrombus formation. One of the abnormalities presented to the platelets during hypertension is an elevated plasma concentration of serotonin (5-HT) caused by reduced 5-HT uptake secondary to loss of the 5-HT transporter (SERT) on the platelet plasma membrane. In the current study, we evaluated platelet function after 7 days of subcutaneous Ang II infusion to establish hypertension in mice and additionally assessed the biology of isolated platelets exposed to Ang II . The administration of Ang II elevated systolic blood pressure, but markers of platelet activation including P-selectin and Jon/A staining were not changed. However, the aggregation response to collagen was reduced in isolated platelets from Ang II-infused mice, which also showed reduced 5-HT uptake by SERT. exposure of isolated platelets to Ang II also resulted in a loss of surface SERT associated with a reduced aggregation response to collagen. These abnormalities were reversed by increasing concentrations of the Ang II receptor antagonist, valsartan. Interestingly, SERT KO mice failed to fully develop hypertension in response to Ang II infusion and isolated platelets from these animals were insensitive to the anti-aggregatory influence of Ang II. Thus, Ang II blunts the aggregation responses of platelets and the mechanism underlying this action may involve a loss of SERT on the platelet plasma membrane. The latter event depletes intracellular 5-HT in platelets, an event that is associated with reduced aggregation. The widespread use of antihypertensive drugs that target the renin-angiotensin system suggest the potential clinical utility of our findings and emphasize the importance of understanding the impact of Ang II on platelet function.
血管紧张素 II(Ang II)是肾素-血管紧张素系统的关键组成部分,与高血压的发生有关。尽管高血压患者血液中的血小板具有异常的生物学特性,但尚不清楚循环中的 Ang II 是否会影响血小板聚集或血栓形成。高血压期间血小板出现的异常之一是血浆中血清素(5-HT)浓度升高,这是由于血小板质膜上的 5-HT 转运体(SERT)丢失导致 5-HT 摄取减少所致。在本研究中,我们评估了皮下注射 Ang II 7 天以诱导小鼠高血压后血小板的功能,并额外评估了暴露于 Ang II 的分离血小板的生物学特性。注射 Ang II 可使收缩压升高,但包括 P-选择素和 Jon/A 染色在内的血小板活化标志物并未改变。然而,来自注射 Ang II 小鼠的分离血小板对胶原蛋白的聚集反应降低,同时 SERT 介导的 5-HT 摄取也减少。将分离血小板暴露于 Ang II 也会导致表面 SERT 丢失,同时对胶原蛋白的聚集反应降低。这些异常可通过增加血管紧张素 II 受体拮抗剂缬沙坦的浓度来逆转。有趣的是,SERT 基因敲除小鼠对注射 Ang II 未能完全产生高血压反应,并对 Ang II 的抗聚集作用不敏感。因此,Ang II 减弱血小板的聚集反应机制可能涉及血小板质膜上 SERT 的丢失。后一事件会耗尽血小板内的 5-HT,这一事件与聚集减少有关。广泛使用针对肾素-血管紧张素系统的降压药物提示了我们研究结果的潜在临床应用价值,并强调了了解 Ang II 对血小板功能影响的重要性。